- Home
- ULCC vs CVAC Comparison
ULCC vs CVAC Comparison
Compare ULCC & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULCC
- CVAC
- Stock Information
- Founded
- ULCC 1994
- CVAC 2000
- Country
- ULCC United States
- CVAC Germany
- Employees
- ULCC N/A
- CVAC N/A
- Industry
- ULCC Air Freight/Delivery Services
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- ULCC Consumer Discretionary
- CVAC Health Care
- Exchange
- ULCC Nasdaq
- CVAC Nasdaq
- Market Cap
- ULCC 1.1B
- CVAC 1.2B
- IPO Year
- ULCC 2021
- CVAC 2020
- Fundamental
- Price
- ULCC $5.51
- CVAC $5.37
- Analyst Decision
- ULCC Hold
- CVAC Hold
- Analyst Count
- ULCC 10
- CVAC 3
- Target Price
- ULCC $5.17
- CVAC $6.83
- AVG Volume (30 Days)
- ULCC 4.4M
- CVAC 475.8K
- Earning Date
- ULCC 10-28-2025
- CVAC 11-11-2025
- Dividend Yield
- ULCC N/A
- CVAC N/A
- EPS Growth
- ULCC N/A
- CVAC N/A
- EPS
- ULCC N/A
- CVAC 1.01
- Revenue
- ULCC $3,778,000,000.00
- CVAC $599,540,810.00
- Revenue This Year
- ULCC $1.48
- CVAC N/A
- Revenue Next Year
- ULCC $13.13
- CVAC $23.95
- P/E Ratio
- ULCC N/A
- CVAC $5.32
- Revenue Growth
- ULCC 4.60
- CVAC 675.15
- 52 Week Low
- ULCC $2.89
- CVAC $2.37
- 52 Week High
- ULCC $10.26
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- ULCC 61.41
- CVAC 48.14
- Support Level
- ULCC $5.15
- CVAC $5.34
- Resistance Level
- ULCC $5.71
- CVAC $5.41
- Average True Range (ATR)
- ULCC 0.36
- CVAC 0.04
- MACD
- ULCC 0.00
- CVAC -0.00
- Stochastic Oscillator
- ULCC 61.50
- CVAC 55.56
About ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.